Tech Company Financing Transactions
ApoVax Funding Round
ApoVax, operating out of Louisville, scored $125 thousand in funding from private investors.
Transaction Overview
Company Name
Announced On
11/26/2012
Transaction Type
Debt
Amount
$125,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1044 East Chestnut St.
Louisville, KY 40204
USA
Louisville, KY 40204
USA
Phone
Website
Email Address
Not Recorded
Overview
ApoVax, Inc. is based on the work of Haval Shirwan, Ph.D. at the University of Louisville. ApoVax104, an immunostimulatory adjuvant construct, consists of streptavidin fused to the costimulatory molecule 4-1BBL. It is well differentiated from other adjuvants.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Lynch
Chief Operating Officer
Patricia Beckmann
Chief Scientific Officer
Haval Shirwan
VP - Bus. Development
Andrew Steen
VP - R & D
Kathryn MacLeod
Browse more venture capital transactions:
Prev: 11/23/2012: FluoroPharma Medical venture capital transaction
Next: 11/26/2012: Maker Studios venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs